XBiotech Inc. (Nasdaq: XBIT) reported positive results from its European Phase III clinical study of its colorectal cancer treatment Xilonix. Shares of the biopharmaceutical surged $4.42 to close at $13.03.
XBiotech reports positive study data
December 07, 2015 at 16:21 PM EST
